Vir Biotechnology (VIR) is in focus after its second quarter 2026 report showed revenue of US$238.95 million and net income of US$80.08 million, compared with losses and minimal revenue a year earlier.

At a share price of US$9.11, Vir Biotechnology has seen a 7 day share price return of 5.44% and a year to date share price return of 53.37%. The 1 year total shareholder return of 79.33% sits against weaker 3 and 5 year total shareholder returns, suggesting recent momentum has picked up even as longer term holders have seen sizable value erosion.

If Vir Biotechnology’s recent earnings have you rethinking exposure to the sector, this can be a good time to survey other healthcare focused AI opportunities through the 42 healthcare AI stocks.

Vir Biotechnology’s strong quarterly swing into profit sits against a share price that still trades far below the average analyst target. Is the recent rally already enough, or does fair value sit meaningfully higher on key measures?

Most Popular Narrative: 58% Undervalued

Analysts see fair value for Vir Biotechnology at about $21.56 per share, which sits well above the recent $9.11 close and suggests a sizeable valuation gap.

The analysts have a consensus price target of $21.56 for Vir Biotechnology based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $16.0.

Read the complete narrative. Read the complete narrative.

The fair value narrative relies on assumptions about revenue, margins, and a premium future earnings multiple. Want to understand which assumptions have the greatest influence on the model and what would need to occur for Vir Biotechnology to close that gap?

Result: Fair Value of $21.56 (UNDERVALUED)

However, the Vir Biotechnology narrative still hinges on unproven therapies and successful regulatory outcomes, so delays or weak trial data could quickly challenge the current valuation gap.

Another View: Vir Biotechnology looks expensive on sales

While the analyst narrative suggests Vir Biotechnology is undervalued against a US$21.56 fair value, the current P/S ratio of 23.5x implies a very different story. That multiple is higher than both the US Biotechs industry at 11x and peers at 21.5x, and far above the fair ratio of 0x, which points to meaningful valuation risk if expectations ease.

For a closer look at how this pricing compares with the numbers the valuation work is based on, check the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around Vir Biotechnology is clearly split, so it makes sense to review the data yourself and weigh both sides before reacting. To see how the risks and rewards balance out in one place, take a closer look at the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Vir Biotechnology?

If Vir Biotechnology has sharpened your focus on where capital could work harder, do not stop here. The right shortlist can shape your next few moves.

• Spot potential turnaround opportunities early by scanning 19 elite penny stocks with strong financials before the crowd pays attention.
• Zero in on quality at a discount by using the 51 high quality undervalued stocks so you are not overpaying for growth potential.
• Prioritise resilience and sleep easier at night by filtering through the 79 resilient stocks with low risk scores instead of guessing which stocks carry hidden issues.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.